COMPANY RESEARCHOffers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY IFRS / consolidated | 1,729,446,000 | 219,761,000 Net income/(loss) attributable to owners of the parent | 232,225,000 | Original ↗ |
| 2026H1 2026-06-30 | CNY IFRS / consolidated / unaudited interim | 1,006,519,000 | 80,077,000 Net income/(loss) attributable to owners of the parent | 346,028,000 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Offers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
A dedicated PROTAC / molecular glue page lists protein production, crystallography, screening, binding kinetics, drug metabolism, bioassays, and AIDD/CADD, plus custom PROTAC design and synthesis.
Combines structural biology and discovery CRO, Langhua CDMO/CMC, and incubation/investment. Investment fair-value changes affect group profit.
Listed as HKEX 01873; original 2025 annual and 2026H1 reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Cyclic peptide discovery and development services | Client-dependent · Client-dependent | 未披露 | Client results not disclosed |
| Structure-based PROTAC / molecular glue discovery and synthesis | Program-dependent / not disclosed · Determined by the collaboration program | Platform / services | This record does not claim platform-wide human validation |
| CRO / CDMO / incubation platform | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
